GlassScriptPhysician profile
Christin B Destefano
NPI 1124388384
$3,157.08
in general payments reported to CMS, 2019-2025
39 companies · $394 in 2025
The $394 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $655 · 2020: $279 · 2021: $81.79 · 2022: $196 · 2023: $909 · 2024: $643 · 2025: $394.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,946.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,945.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $342.45 | 2019-2025 | Venclexta |
| E.R. Squibb & Sons, L.L.C. | $238.36 | 2019-2022 | |
| Karyopharm Therapeutics INC. | $217.00 | 2023-2025 | Xpovio |
| Incyte Corporation | $208.68 | 2019-2025 | Monjuvi, Jakafi, Niktimvo |
| Genzyme Corporation | $208.64 | 2019-2025 | |
| Mirati Therapeutics, INC. | $163.01 | 2023-2024 | Krazati |
| Jazz Pharmaceuticals INC. | $143.43 | 2024 | |
| Exelixis INC. | $129.22 | 2019-2025 | Cabometyx |
| Celgene Corporation | $122.61 | 2020-2023 | Pomalyst |
| Gilead Sciences, INC. | $122.35 | 2023-2025 | Trodelvy |
| Kyowa Kirin, INC. | $121.73 | 2023 | Poteligeo |
| Merck Sharp & Dohme LLC | $114.40 | 2019-2025 | Keytruda, Keytruda Qlex |
| Daiichi Sankyo INC. | $99.26 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $80.39 | 2019-2024 | |
| Morphosys, US INC. | $67.77 | 2022-2024 | Monjuvi |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genmab U.S., INC. | $65.53 | 2025 | Epkinly |
| Alexion Pharmaceuticals, INC. | $63.57 | 2022-2023 | Ultomiris |
| Pharmacyclics LLC, An Abbvie Company | $61.55 | 2023 | Epkinly |
| Sobi, INC | $48.87 | 2024-2025 | |
| Coherus Oncology, INC. | $45.97 | 2024 | |
| Recordati_rare_diseases_inc. | $45.18 | 2023-2024 | Sylvant |
| Aveo Pharmaceuticals, INC. | $42.62 | 2021-2024 | |
| Amgen INC. | $39.03 | 2019-2023 | Lumakras |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.59 | 2019-2021 | |
| Eisai INC. | $31.15 | 2019-2020 | |
| Genentech USA, INC. | $28.82 | 2019 | |
| Seagen INC. | $28.51 | 2020 | |
| Alnylam Pharmaceuticals INC. | $27.99 | 2023 | Givlaari |
| Tersera Therapeutics LLC | $26.19 | 2023 | Xermelo |
| Glaxosmithkline, LLC. | $24.87 | 2022 | |
| Adc Therapeutics America, INC. | $23.94 | 2024 | |
| Immunogen, INC. | $23.27 | 2023 | Elahere |
| Rigel Pharmaceuticals, INC. | $22.91 | 2023 | Rezlidhia, Tavalisse |
| Beone Medicines USA, INC. | $22.02 | 2025 | Tevimbra |
| Btg International INC. | $19.17 | 2025 | Voraxaze |
| Tesaro, INC. | $18.87 | 2019 | |
| Clovis Oncology, INC. | $17.16 | 2021 | |
| Amag Pharmaceuticals, INC. | $15.00 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christin Destefano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.